

**KRISHNASWAMI VIJAYARAGHAVAN, MD
(KRIS VIJAY, MD)**

PRESENT POSITIONS

1999-Current:	Heart Failure Cardiologist
Nov 2022- current	Cardiac Medical Director, Arizona Heart Foundation
2014- current	Clinical Professor of Medicine, University of Arizona, Phoenix
2016-current	President, Innovative Cardiometabolic Center, Inc
2016- current	Chief Medical Officer, Aventyn, A Biotech Digital health solutions company
2008-current	Adjunct Professor of Medicine Midwestern University College of Medicine Glendale, AZ
2010- current	President, Twinepidemic, Inc
2018- current	Associate Editor, Journal of Clinical Lipidology
Aug 2022- current	Chief Research Officer, Rovicare
March 2022- Current	Chief Science Officer, 8 Chili, Inc

IMMEDIATE PAST POSITIONS:

2016- Oct 2021	Medical Director, CHF Heart Failure Cardiologist and Non-invasive Cardiologist, Abrazo Arizona Heart Institute and Hospital, Phoenix, AZ
2004- 2016	Heart Failure Cardiologist and Noninvasive Cardiologist Scottsdale Cardiovascular Center, P.C. 3099 Civic Center Plaza Scottsdale, AZ 852512017-2018
2016-2018	Executive Board Member, Medical Executive Committee, Abrazo Arizona Heart and Arrowhead Hospital
2012- 2016	Chair, Scientific Review Committee, Scottsdale Healthcare Research Institute, Scottsdale Healthcare
2010- 2016	Vice President, Scottsdale Cardiovascular Center, Scottsdale, Arizona
2011- 2014	Past President, Cardio Renal Society of America, (CRSA)
2014- 2015	Past President, National Lipid Association, Southwest chapter
2008-2012	Medical Director, Cardiovascular Research, Scottsdale Healthcare, Scottsdale, Arizona
2013- 2015	Member, Steering committee: "Ombudsman" for Region IX of Regional Health Equity Council, Office of Minority Health, Dept. of Health and Social Services, USA
2010- 2013	Past Governor, Arizona Chapter of American College of Cardiology and Member of BOG, ACC National.
Dec 2004 – Aug 2016	Non-invasive Cardiologist and Heart Failure Medical Director, Scottsdale Cardiovascular Center, Scottsdale, Arizona
July 1999 – Nov 2004	Noninvasive Cardiologist, Medical Director, CHF program and Director of Clinical Research, Arizona Heart Institute. Phoenix, Arizona

EDUCATIONAL BACKGROUND

**UNIVERSITY OF BOMBAY, Bombay, India
Bachelor of Science, 1972**

**UNIVERSITY OF MYSORE, Mysore, India
Kasturba Medical College
MBBS (MD), 1979**

**UNIVERSITY OF MICHIGAN
Master of Science (MS) in Clinical Research Design and Statistical
Analysis, May 1995**

POST GRADUATE EXPERIENCE

**July 1996- Fellowship in the Dept. of Cardiology at
July 1999 Good Samaritan Medical Center, Phoenix, University of Arizona**

**Nov 1990- Attending in Primary Care Internal Medicine and
July 1996 Chief of Diabetes, CIGNA Healthcare of Arizona
Clinical Instructor at Good Samaritan Regional Medical Center,
Phoenix, AZ**

**July 1989- Clinical Instructor and Primary Care Internist at St. Mary's Hospital,
Oct. 1990 University of Rochester, New York.**

**July 1986- Internal Medicine Residency at St. Mary's Hospital,
June 1989 University of Rochester, Rochester, New York**

**July 1985- General Surgical Residency, Bronx Lebanon Hospital, Albert Einstein
July 1986: University, Bronx, New York**

**Oct 1984- Clinical Assistant, Lapeer Medical Center, Michigan, USA
July 1985**

In U.K:

**Nov. 1983- Fellowship in Endocrinology and
Oct 1984 Diabetes at St. Mary Hospital, Isle of Wight, University of
Southampton, UK**

Aug 1983 - Oct 1983 Registrar and Senior Registrar, Geriatric Medicine at North Manchester General Hospital

Aug 1981- July 1983 General Internal Medicine Residency at Kettering General Hospital, Kettering, Oxford Regional Authority, UK

Mar 1981- Jul 1981 Locum Tenens at Rushden Hospital and Newark General Hospital

In INDIA:

Jun 1977- Jun 1979 Internship and Residency in Internal Medicine and Nephrology, at LTMG(Sion) Hospital and KEM Hospital, Bombay (MD)

July 1979- Feb 1981 Residency in General Surgery and Faculty, Emergency Medicine, Holy Family Hospital, New Delhi

CERTIFICATIONS

FHFSA: Fellow of the Heart Failure Society of America, Sept 2016
FCRS: Fellow of the Cardio-Renal Society of America, March 2016
FNLA: Fellow of the National Lipid Association (FNLA), 2010
Board Certification from American Board of Clinical Lipidology, Sep 2007 and recertification Aug 2018
FCCP: Fellow of the American College of Chest Physicians (FCCP) 2004
FACC: Fellow of the American College of Cardiology (FACC) 2001
Advanced Heart Failure training, 1998-99
Board Certified in Cardiovascular Medicine 1999
Board Recertification in Cardiovascular Medicine May 2009
FACP: Fellow of the American College of Physicians (FACP) 1997
MS: Master of Science, Clinical Research Design and Statistical Analysis 1995
Board Certified in Internal Medicine 1988
MBBS (MD) 1979
ACLS 2018- 2020

TEACHING EXPERIENCE:

Teaching medical Students, residents and fellows from 1989 till now under the aegis of a teaching program

- Clinical Instructor: University of Rochester: 1989-1990**
- Clinical Instructor and Clinical Scholar: Good Samaritan Medical Center, Phoenix, AZ; 1990- 1996**
- Assistant Professor of Medicine: Good Samaritan Medical Center, University of Arizona, 1996- 1999**

- Associate Professor of Medicine, Midwestern College of Medicine, Arizona: 2000- 2004
- Professor of Medicine, Midwestern College of Medicine: 2004 – current
- Clinical Professor of Medicine, University of Arizona: 2014 – current
- Faculty, Scottsdale Healthcare Family Medicine Residency Program: 2009-current
- Mentor, Scholarly project for students at University of Arizona Medical School, Phoenix, 2014- 2021
- Mentor, Community Clinical Experience, U of Arizona, Phoenix. 2014-2021
- Faculty, Abrazo IM Residency Program 208- current
- Director of Research, Abrazo Residency Program, 2018- 2022
- Mentor, Capstone Project, U of Arizona, Phoenix, 2018- 2021
- Mentor, Research Projects U of AZ , Phoenix 2021- current
- Judge Scholarly project Research, U of AZ, Phoenix, 2017- current
- Case Based Instruction U of AZ, Phoenix, 2021- current
- Active Learning, Flipping the Classroom, U of AZ, Phoenix 2023- current

AWARDS AND RECOGNITION:

1. Founding member of Arizona Managed Care Quality Enhancement Program (AMCQEP), Health Services Advisory Group (HSAG). October 2002
2. President's Award for Innovation for Center for Healthcare Innovation & Clinical Trials (CHI & CT), Arizona State University, 2010
3. Distinguished Career award, South Asian Society for Atherosclerosis and Thrombosis, Dec 2010, Bangalore, India
4. Jerome Markowitz award for Distinguished career achievement by SASAT in 2013
5. American College of Cardiology Award in 2013 for 3 years of prolific work in pursuit of quality education, mutually beneficial partnership, and advocacy.
6. American Association of Cardiologists of Indian Origin (AACIO): Special award for contributions in cardiology, March 2014
7. Special Service award, National Lipid Association, 2015
8. Nominated for Phoenix Business Journal's Healthcare Heroes award in the "Lifetime achievement" category, June 2017
9. Lifetime achievement award, American College of Cardiology, Arizona Chapter, May 2018
10. Special service award, Mended Hearts, 2018
11. Arizona Business Magazine's Health Care leaders of Arizona , AZ BIG Media AZ Business , May 2019
12. AZ Top Docs 2020, 2021 and 2022
13. Author : Invoking your inner therapist in Heart Failure: Untold Patient experiences from Prevention to End Stage, Launched October,2, 2020
14. Finalist , Lifetime Achievement award. Phoenix Business Journal

- Healthcare Heroes award, Nov 2020
15. Chapter President's Service Award, National Lipid Association, December 2020
16. Spotlight , Shoutout Arizona, Aug 2022
<https://shoutoutarizona.com/meet-kris-vijay-doctor/>
17. Lifetime Achievement award, Alana Foundation, Oct 2022

RELEVANT PROFESSIONAL AFFILIATIONS AND BOARD MEMBERSHIPS

- Member, Heart Failure Society of America, 1999-present
- Member, American Heart Association, 2000-present
- Member, Steering Committee, Cardiovascular Section, "CHEST", 2002-2006
- Member, Editorial Board, "American Heart Hospital Journal", 2002- 2009
- Member, Editorial Board, "CardiologyResearch.org": a web-based cardiology journal, 2003-present
- Chairman CME committee, American Association of Physicians of Indian Origin (AAPI), 2005-2007
- Member, National Lipid Association, 2006-present
- Member, Executive Board, Southwest Chapter, National Lipid Association, 2009- current
- Chair, CME Committee, American College of Cardiology, Arizona Chapter, 2006 –2009
- Member, ECHO Appropriateness Technical Panel, American College of Cardiology, 2006- present
- Vice Chair, Heart Disease section of India Health Initiative (IHI) sponsored by Govt. of India and WHO: Jan 2007 – 2017
- President, Task Force on Twin Epidemics of Diabetes and Heart disease among in South Asian Community, (Twinepidemic: A Nonprofit corporation) 2007- present
- Member, Executive Committee, Center for Healthcare Innovation and Clinical Trials (CHI&CT), Arizona State University, 2008- 2012
- Director, Education Committee, Scottsdale Healthcare, Osborne campus: 2007 – present
- Chair, Scientific Review Committee, (SRC) Scottsdale Healthcare, 2008-present
- Co director, Evidence Based Medicine Course, Midwestern University School of Medicine, Arizona, 2009
- Member, Steering Committee, Cardiovascular Medicine and Surgery Section, American College of Chest Physicians, 2008-2012
- Member, Board of Governors, American College of Cardiology.

- **Member, CREDO Advisory Group. (*Coalition to Reduce Racial & Ethnic Disparities in CV Outcomes.*), American College of Cardiology. 2009-2114 present**
- **Co Chair, Awards committee, American Diabetes Association, Phoenix, AZ Chapter. 2009- 2011**
- **Member, Executive Board, Arizona Cardiac Center Consortium. 2010- present**
- **Member of the Advisory Board of National Diabetes, Obesity and Cholesterol Disorders Foundation, India (N-DOC) 2010- present**
- **Member, International Committee, American College of Cardiology, 2010- present**
- **Officer position as Secretary, National Lipid Association (Southwest Chapter), 2011- 2012**
- **Officer position as Treasurer, NLA, Southwest Chapter, 2012-2013**
- **Director, Mountain Region, Executive Committee, American Association of Physicians of Indian origin (AAPI), 2011- 2012**
- **Member Regional Health Equity Council for Region 9, Office of Minority Health, DHSS. September 2011- 2017**
- **Member, Institutional Review Board (IRB) Scottsdale Healthcare, 2012 – current**
- **Co-Chair, cardiology Track, Global Health Summit, Cochin, 2013. www.aapiighsindia.org**
- **Member Cardiometabolic work Group, ACC, 2013- current**
- **Member, ACPNet Diabetes Group steering committee, 2013-current**
- **Member, Topic Group expert “Epidemiology and Prevention”, World Congress on Cardiology, World Heart Federation, 2013-current**
- **Member, Editorial Board, Cardiorenal Medicine Journal, 2013-current**
- **Member, India Advisory Board, American College of Cardiology, 2012- current**
- **Member, Steering committee: “Ombudsman” for Region IX of Regional Health Equity Council, Office of Minority Health, Dept. of Health and Social Services, USA, 2013- current**
- **Member of Endocrine Committee for the National Quality Forum, 2013- current**
- **Co-Chair, Consensus Panel on Cardiorenal Prevention and Intervention among South Asians, San Francisco, July 2014**
- **Member, Consensus panel, AACE/ACE Consensus Conference on Glucose Monitoring, Sept 2014**
- **Member, Research and Publication Committee, PINNACLE INDIA Registry, American College of Cardiology. 2014- current**

- **Member, Steering Committee, National Forum on Cholesterol Awareness, 2014- current**
- **Member, Heart Disease and Stroke Work Group, Arizona Department of Health Services. 2014- 2015**
- **Executive Board Member, National Lipid association, 2015- 2022**
- **Member, Cardiometabolic Work Group, American College of Cardiology, 2015 – current**
- **Member, Disparity Work Group, American College of Cardiology, 2015- current**
- **Chair, Project Review Committee, National Lipid Association, 2015- current**
- **Chair, Data Safety Monitoring Board, Research study, Baylor, Texas: 2016- current**
- **Member, Advisory Board, Journal of Diabetology, 2016- current**
- **Member, KDIGO, “Controversies Conference on Heart Failure in CKD” May 2017, Athens, Greece**
- **First Cardiorenal Center in USA inauguration Oct 2017**
- **Member, Editorial Board, Annals of Clinical Cardiology: 2018 - current**
- **Associate Editor, Journal of Clinical Lipidology, 2018- current**
- **Executive Council Chair, National Lipid Association, 2018- current**
- **Chair, Practice Management Council, NLA, 2018- 2020**
- **Co-Chair, South Asian Working Group, National Lipid Association, 2018- current**
- **Member, Editorial Board, Reviews in Cardiovascular Medicine, 2019- current**
- **Advisory Board member, Multiple Pharmaceutical and Device industries in Lipids, Diabetes Heart disease and Heart Failure, Kidney disease.**

VOLUNTEERING FOR NON-PROFIT ORGANIZATIONS

- **Path to Wellness project, Cardiorenal Society of America**
- **Twinepidemic, Inc: Nonprofit serving ethnic communities all over the world**
- **Ladakh Heart Foundation Cardiorenal Screening project, Leh, Ladakh, 2014**
- **Volunteering for NLA Foundation projects**
- **Volunteer Ombudsman, Office of minority health, Regional Health Equity IX**
- **South Asian Society of Atherosclerosis and Thrombosis (SASAT)**
- **“credo” Project, American College of cardiology**
- **World Heart Federation prevention committee projects**
- **Member, Executive Committee, National Forum: Cholesterol Awareness project for medical and non-medical community**
- **Volunteer for Mended Hearts**
- **Volunteer and Needs Assessment specialist for Project C.U.R.E**

- Volunteer, Gila River Native Indian Community Career Fair, Oct 2022

MOST RECENT RELEVANT CME PRESENTATIONS:

2017- 2023:

Newer frontiers in dyslipidemia: JIC 2017, Jan 2017, Ahmedabad, India

Atrial Fibrillation: At cardiorenal University, Anaheim, CA May 2017

KDIGO, “Controversies Conference on Heart Failure in CKD” Athens, Greece, May 2017

“Managing CV Disease Risk in Diabetes Roundtable” American College of Cardiology, June 2017

Diabetes and Cardiovascular disease: Cardiology perspective, A Symposium at Cardiorenal Society of America, Oct 2017

Icosapent Ethyl Reduces Potentially Atherogenic Lipid and Inflammatory Markers in High-Risk Statin-Treated Patients with Stage 3 chronic kidney disease and Persistent High Triglycerides: A Rapid-Fire presentation at American Heart Association Annual Scientific Session, Anaheim, Ca Nov 2017

Optimizing Diabetes Management for Cardiovascular Outcomes: Novel Agents and the Roles of Conventional Antidiabetic Therapies: It’s Not All About Glycemic Control Anymore. Cardiometabolic University meeting, Dallas, Dec 2017

Evolving strategies in Heart Failure management, Abrazo TED conference, March 2018

Presentation at Joint Symposium of Cardiorenal Society and IRRIV on AKI and CRRT, June 2018, Vicenza, Italy

Faculty and Co- Chair, CME Cruise Conference, Alaska, Update in Cardiology to Primary Care, Sept 2018 (Total 14 hours of CME)

Presentation on Lipid update to Primary Care, Arizona Diabetes Foundation conference, Scottsdale, AZ, sept 2018

Presentation on Diabetes and CV outcomes, Arizona Diabetes Foundation conference, Scottsdale, AZ, sept 2018

Chair, Round Table discussion: “Rampant Increase in Diabetes and Heart Disease Among South Asians: Invoking the Urgent Need to Prevent This Epidemic”, American Heart Association satellite symposium, Chicago, Nov 2018

Chair, “Lipidology - An Overview for the Clinician”, Cardiological Society of India, Annual Convention, Mumbai, India, Nov 2018

**Chair, “Demystifying Age Old CCU Dilemmas - Simplified Approach”,
Cardiological Society of India, Annual Convention, Mumbai, India, Nov 2018**

**Faculty and Chair, Nursing Symposium, 10-part series on “Update in Cardiology
for Nurses”, Abrazo Health Network, Dec 2018- March 2019**

**Presentation on “Cardiorenal Syndrome” at Innovations in Cardiovascular Care,
Tenet Symposium, February 14th-15th, 2019 at the J.W. Marriott Desert Ridge in
Phoenix, Arizona.**

**Participation in Public Forum at Innovations in CV care Tenet Symposium, Feb
15, 2019, Phoenix, AZ**

**Presentation on “Managing cardiorenal metabolic conditions in patients with
Diabetes” at Southwest Diabetes Symposium, Tucson, March 16, 2019**

**Presentation on “Managing cardiorenal metabolic conditions in patients with
Diabetes” at Southwest Diabetes Symposium, Yuma, April 13, 2019**

**Presentation on “REDUCE -IT” clinical trial on EPA and CV disease at
Cardiometabolic Health Congress , May 3, 2019**

Chair, session on “Lipid Guidelines” at NLA annual convention, Miami May 2019

**South Asian Symposium, “Diabetes, Heart disease and Dyslipidemia connectome
in SA” May 17, 2019**

**Keynote address on “Healthy and Whole is Heart and Soul” NABI Foundation,
First Annual Youth Summit, June 2019**

**Presentation on “Diabetes and CV Outcomes” at ACC Arizona Annual meet, June
2019**

**Lp(a) and CV disease: Lipid Association of India Annual Convention: Aug 17-18,
2019**

Chair session on Lifestyle modification: LAI, Delhi: Aug 17-18, 2019

**Co- Chair: b-e care: Intersection of Cardiometabolic Renal disease and
technology: Bangalore, India : Aug 19-21, 2019**

JIC International : Virtual session: Heart Failure update May 2020

JIC International : Lipid update , Virtual, May 2020

Message of Hope Podcast: Oct 2020: <https://speakerspathway.com/kris-vijay/>
Non CME

Primed Talks: April 2021, May 2021, Nov 2021 (All CME)

Presentation at Heart Failure Society of America, Denver, CO.: Diabetes and Heart Failure: Sep 2021

Presentation on Diabetes and Heart Failure, Las Vegas, Nevada, AACE, Nevada Chapter Biannual convention, Oct 2021

Dec 2021, Podcast on Cardiorenal metabolic disease prevention:
<https://www.facebook.com/watch/?v=486360539813676>

Podcast Feb 2022: <https://trianglespotlight.net/2142022-kris-vijay-barbara-ten-brink-vito-altavilla-kat-karamitros-sandra-lee-reynolds>. Non CME

Presentation on update of HFrEF and HFpEF: Nevada CEA biannual convention, Reno, NV , April 2022

Presentation on Patient engagement at Annual convention, ACC, Washington DC April 2022

Presentation on Diabetes and CVD: Southwestern Osteopathic conference, Tucson, AZ , April 2022

Presentation on Gender disparities in Diabetes and Heart disease among South Asians, Annual Convention, AACE, San Diego, May 2022

Presentation on Lp(a) and CVD : Lipid Association of India Annual convention Aug 2022, New Delhi, India

“Prevention of Cardiometabolic Renal disease : Primordial to Tertiary” : HOLD MEDICON 2022, Virtual CME conference, Sep 18, 2022

Clinical Trials with Immersive Hint VR Platform for customizable CV care: AZ Bio annual meet, Phoenix, AZ, Sep 2022

ATTR -CM: Presentation on Cardiac amyloidosis, Champions for Health, National Pharmacy association, Anaheim, CA, Nov 2022.

Presentation : Healthy and whole is Heart and Soul: IAGCH Dec 4th, 2022.
<https://www.youtube.com/watch?v=zTOgvGew3ul>

Co-Chair, and Presentation at Amyloidosis Symposium, Jan 14th, 2023. Arizona State University, Dept of Future Health.

https://theifh.org/wp-content/uploads/2023/01/Agenda_CardiacAmyloidosisCME-FINAL-Online.pdf

Series Director, PODCAST for Arogyaseva. VIDYA ROPANA: Holistic Healing through knowledge. February 2023- ongoing

Presentation on “Update in Heart Failure recovery and management”: Annual Southwestern conference on Medicine, Tucson, Z. April 2023

Webinar Spotlight: Cardiovascular disease in South Asians: Cardiometabolic Health Congress Webinar series. May 2023.

<https://www.cardiometabolichealth.org/resources/webinar-spotlight/>

Presentations on Cardiology topics for Medical Education Resources (MER) on “ Internal Medicine for Primary Care” at Yosemite, CA, July 2023

Co-moderator, Cardiac Amyloidosis Research Symposium (CARS), Arizona State University, Department of Future Health, Aug 2023

2009- 2017

Plenary session on “Metabolic syndrome in the Intensive Care” at the Annual CHEST convention, Nov 3rd, 2009, San Diego

Chair, Interactive session on “Pericardial disease for the Intensivists”, Annual CHEST convention, Nov 3rd, 2009, San Diego

Keynote address: “Reflections from practice of Medicine” American College of physicians, Arizona Chapter, March 2010

Grand Rounds: “Newer research in Cardiovascular Medicine”, Scottsdale Healthcare, March 2010

Invited Lecture “Diabetes and Heart disease” Diabetes EXPO, April 2010

Invited lecture: “Optimal management of CHF” AAPI annual convention, July 2010, Washington, DC

Chair, “Quelling the Twinepidemic of Diabetes and Heart disease in South Asian Community”, Satellite symposium, Vancouver, CHEST annual convention, Oct 2010

**Chair, “Twinepidemic of Diabetes and Heart disease in South Asian Community”
Spotlight session, Convention center, CHEST 2010 Annual convention,
Vancouver, Canada**

**Chair, “Telemedicine in Cardiovascular Disease” Symposium, CHEST Annual
convention, Oct 2010, Vancouver, Canada**

**Keynote address “Inflammation in Metabolic Syndrome: How to weather the
perfect storm”. South Asian Society of Atherosclerosis and Thrombosis”, Dec
2010, Bangalore, India**

**Invited speaker “Optimal treatment strategies in advanced heart failure” Mayo
clinic symposium: “Guidelines in heart failure management”, Feb 2011,
Scottsdale, AZ**

**Keynote address “East meets west: Healthcare in US and India; Challenges and
Opportunities”, Medtronic annual meeting for emerging markets, June 16, 2011**

“Hot Plaques imaging” National Lipid Association Update, India, Sept 2011

“Statin Myopathy”. NLA update, India, Sept 2011

**Presentation at Cardiovascular Consultants CME symposium for primary care
specialists in Scottsdale on “Diabetes: getting to the heart of the Matter”. Feb 10,
2012**

**Presentation at Scottsdale Intervention Forum on CHF: H2H an ACC Initiative, Feb
15, 2012**

**Keynote address on: Triple threat of Diabetes, heart disease and Kidney failure”
at Southwest Kidney Foundation Annual Convention, Feb 17, 2012**

**Co-Chair, symposium: Global Burden of Cardiovascular Disease”, American
College of Cardiology Annual Convention, Chicago, March 2012**

Co-Chair, Symposium: Vitamin D and Cardiovascular Disease” at the World Congress on Cardiology, Dubai, April 2012

Co-Chair, symposium: “Lipoprotein and clinical controversies”, World Congress on Cardiology, Dubai, April 2012

Role of Lp(a) in CV disease. June 1st, 2012, National Lipid Association Annual convention, Scottsdale, AZ

“Cardiodiabetes Prevention”. GAPIO Semi Annual Convention, New Jersey, 2012.

“Aligning goals of AAPI and Cardiologists from India”: Plenary session, Global Health Summit, 2013, Kerala, India

“CVD Reduction beyond LDL” presentation at Annual meeting, SASAT, Coimbatore, India, Jan 2013

“CHF Update”. Presentation at Annual Meeting, SASAT, Coimbatore, India, Jan 2013

Co-Chair “First Annual Convention of Cardiorenal Society of America”, Phoenix, AZ, March 2013

Primed conference, May 3, 2013: presentation on “Newer therapies in hypertriglyceridemia”, Anaheim, CA

“Twinepidemic of Heart disease and Diabetes among South Asian community” spotlight presentation at Semi Annual conference, Global Association of Physicians of Indian Origin: GAPIO”, July 6, 2013, Anaheim, CA.

“The key to evidence-based diabetes care: Effective patient engagement” Presentation at American College of Physicians meeting, Sedona, July 19-20, 2013

“Dyslipidemia for cardiologist” Presentation at second annual Phoenix Heart Symposium, Phoenix, AZ, Sept 28, 2013

“Cardiorenal Society objectives” Presentation at Renal Executive Forum, Sept 29, 2013, Portland, OR.

“Update on 2013 AHA/ACC Lipid guidelines”. Presentation at Bombay Hospital, Mumbai, India, Feb 15, 2014

Chair, Planning Committee, Cardiorenal Society of America, Second Annual Convention, March 2014, Scottsdale, AZ

Co-Chair, National Lipid Association, Clinical Update, Atheroprevention, Emerging concepts and global perspectives, March 2014, Maui, HI, USA

“HDL Hypothesis: new developments” Chair, National Lipid Association meeting, Spring Update, Maui, Hawaii, March 2014

“Recent advances in management of dyslipidemia” Presentation at Annual meeting of American Association of Cardiologists of Indian Origin, March 2014.

“Tackling Diabetes and Heart disease in South Asians; at the individual level” Presentation at the World Heart Federation meeting of the World Congress on Cardiology, May 2014, Melbourne, Australia

“CKD as an independent risk factor of CVD”. Presentation at the World heart Federation meeting of the World Congress on Cardiology, May 2014, Melbourne, Australia

“Consensus on Cardiorenal prevention and intervention among South Asians” Chair and presentations at San Francisco, American Diabetes Association Annual Convention, June 12, 2014.

“Deconstructing the Cardiometabolic components” Cardiometabolic Think Tank meeting, ACC, Washington DC, June 20, 2014

“Hyponatremia in Heart Failure”. Presentation at Loma Linda University, California, Aug 26, 2014

“Reflections in advances in Cardiology over the last 30 years” Keynote presentation, Mended Hearts Annual meeting, Sep 9, 2014

“Current concepts in Heart Failure”: Keynote address, Kasturba medical College, Manipal, India. Oct 7, 2014

“Cardiorenal Syndrome”: Presentation at the annual CAD (Coronary Artery Disease) meeting in Mumbai, India, Oct 10, 2014

“New Biomarkers in Heart Failure”: Grand Rounds Presentation at Medanta Hospital, New Delhi, India, Oct 14, 2014

Presentations at Annual Indian Association of Clinical Cardiology Conference on

“Heart Failure with Preserved ejection Fraction; Extracorporeal Shock Wave Myocardial Revascularization; and Central Aortic BP and Arterial Stiffness”

Ooty, India, Oct 17-19, 2014

“Confronting racial and ethnic disparities in cardiometabolic disease” Symposium participant, cardiometabolic health Congress, Boston, USA, Oct 2014.

“Using Health Information Technology to reduce disparities in health outcomes”. Regional Health Equity council IX annual meeting, Oct 2014, Long Beach, California

Co-Chair, Southwest Lipid Association, Annual spring update, Denver, CO. Feb 27- March 1, 2015

Round Table discussion, Annual session, Cardiorenal Society of America, March1, 2015

Remote monitoring technology in managing chronic diseases: b-e care, Bangalore, India, July 2015

New therapies in Lipidology; primary Care track, Annual meeting, Cardiorenal Society of America, March 2016, Scottsdale, AZ

Cardiorenal Syndrome: An unhappy marriage? Co- chair, session at American College of Cardiology, annual convention, Chicago, April 2016

Disparities in heart disease and diabetes; co-chair, session at ACC annual convention, Chicago, 2016

Non- alcoholic fatty liver disease: Chair, session at National Lipid Association annual convention, New Orleans, May 2016

REVIEWER OF RECENT SENTINEL ARTICLES AND JOURNALS

- **Journal of diabetes and complications**
- **Journal of clinical nutrition**
- **Diabetic Medicine**
- **Cardiorenal Medicine Journal**
- **Official reviewer: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).
<http://www.circulationaha.org> DOI: 10.1161/ CIRCULATION AHA.105.167586. e154- e235**
- **Official reviewer for 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients with Peripheral Artery Disease (Updating the 2005 Guideline). Circulation November 1, 2011 vol. 124, 18 2020-2045**
- **Official reviewer for 2013 Appropriate Utilization of Cardiovascular Imaging: A Methodology for the Development of Joint Criteria for the Appropriate Utilization of Cardiovascular Imaging by the American College of Cardiology Foundation and American College of Radiology
J Am Coll Cardiol. 2013;61(21):2199-2206. doi: 10.1016/j.jacc.2013.02.010.**
- **Journal of Clinical Lipidology**
- **Annals of Clinical Cardiology**
- **Advances in Chronic Kidney Disease**
- **Journal of Global Health**
- **JACC**
- **Journal of Diabetology**

- **Journal of Metabolic Syndrome**

PARTICIPATION IN RESEARCH TRIALS:

CONGESTIVE HEART FAILURE

1. Principal Investigator: OVERTURE - Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events- 1999 - 2002
2. Principal Investigator: IMPRESS - Inhibition of Metalloproteinase by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects with Heart Failure. 1997 - 2002
3. Principal Investigator: ATTACH - A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Pilot Trial Evaluating the Effects of Infliximab (Remicade) in Patients with Stable Class III or IV Congestive Heart Failure. 2000 - 2002
4. Principal Investigator: An Open-Label, Restricted Access, Uncontrolled Study to Assess the Tolerability and Safety of SB 217242 in Patients with Stable NYHA Class I-III Congestive Heart Failure Who Participated in Protocol 073. 1999 - 2000
5. **Principal co-investigator: SCD-Heft - Sudden Cardiac Death in Heart Failure Trial. NIH Sponsored Trial. 1998 - 2004**
6. Co investigator: VECTOR - Biventricular pacing in heart failure. study 2000-2003
7. Principal Investigator: A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCl vs Glyburide in the Treatment of Subjects with Type 2 (Non-Insulin Dependent) Diabetes Mellitus and Mild to Moderate Congestive Heart Failure. 2001- 2004
8. Principal Investigator: FUSION 1 - Management of Patients with CHF After Hospitalization – Follow Up Serial Infusion of Natreacor® - a Pilot Study. 2002 – 2003
9. Principal Investigator: I-PRESERVE - Irbesartan in Heart Failure with Preserved Systolic Function. 2002- 2003

10. Principal Investigator: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Impact of Subcutaneous (SC) Darbepoetin Alfa Treatment on Exercise Tolerance in Subjects with Symptomatic Congestive Heart Failure (CHF) and Anemia 2002 – 2005
11. Principal Investigator: STAMINA-HFP - Study of Anemia in a Heart Failure Population. 2002 – 2004
12. Principal Investigator: ESSENTIAL - A Phase III, randomized, double-blind, parallel group, placebo-controlled study of an inotropic agent in advanced chronic heart failure. 2002 -2005
13. Principal Investigator: REVIVE - Randomized, Multicenter Evaluation of Intravenous Levosimendan Efficacy versus Placebo in the Short-Term Treatment of Decompensated Chronic Heart Failure. 2003 – 2005
14. Principal Investigator: RABBIT - Rapid Assessment of Bedside BNP In Treatment of Heart Failure. 2003 –2005
15. Principal Investigator: EVEREST - Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effects of Tolvaptan on the Outcome of Subjects Hospitalized with Worsening Congestive Heart Failure. 2003 –2006
16. Principal Investigator: ACCLAIM - Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy. 2003 –2006
17. Principal Investigator: FUSION II - Follow-Up Serial Infusions of Natrecor® (nesiritide) for the Management of Patients with Heart Failure. 2004 –2007
18. Principal Investigator: PARTNERS HF - Multi-site Program to Access and Review Trending INformation and Evaluate CoRrelation to Symptoms in Patients with Heart Failure. 2005 – 2007
19. Principal Investigator: COMPARE - A Multicenter, Randomized, Double Blind, Double Dummy, Parallel Group Study to Compare Effects of Coreg CR and Coreg IR on Ejection Fraction in Subjects with Stable Chronic Heart Failure. 2006 – 2008
20. Principal Investigator: RED-HF - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia. 2006 – 2012

21. Principal Investigator: The Effect of Ribose on BNP Levels in Congestive Heart Failure Patients. 2006 - 2008
22. Principal Investigator: Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND Trial) from 12/17/08 – 2010
23. Principal Investigator: A Randomized, Multicenter Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Rivaroxiban in Subjects with Acute (Open-Label, Active-Controlled) or Chronic (Double-Blind, Placebo-Controlled) Congestive Heart Failure IMPACT Trial .12/19/07 – 2009
24. Principal Investigator: An Observational Prospective Registry to Identify Demographic and Clinical Characteristics of Patients Hospitalized with Euvolemic and Hypervolemic Hyponatremia and Assess the Comparative Effectiveness of Available Treatments and the Impact on Resource Utilization. Sept 2011- 2014
25. Principal Investigator, AVOID HF: 2013- 2016
26. Principal Investigator, Assess Measurements of Wireless Cardiac Output Device (Remote-CO-1). 2014- 2015
27. Sub Investigator, APOLLO INTREPID clinical trial, 2017- current

LIPIDS

1. Co-investigator: RAMPART - Relative and Absolute Myocardial Perfusion changes as measured by position emission tomography to assess the effects of ACAT inhibition; a double blind, Randomized Multicenter Trial. 1998 – 2000
2. Principal Investigator: A double-blind Comparison of 10, 20, 40 and 80 mg Doses of a Modified-Release Formulation of Pravastatin, of Atorvastatin 10, and of Simvastatin 20 mg with Placebo in Hypercholesterolemic Subjects. 1999-2001
3. Subinvestigator: Evaluation of the Safety and Efficacy of Nicostatin™ (a combination tablet of niacin extended-release/lovastatin immediate-release): An Open-Label Extension Study. 1999 – 2001

4. Subinvestigator: A 24-week Randomized Double-Blind Multicenter Trial to Evaluate the Efficacy and Safety of Starting and Maximum Doses of ZD4522 and Atorvastatin in the Treatment of High Risk Hypercholesterolemic Subjects. 1999-2000
5. Subinvestigator: A 12-week Multicenter Randomized Double-blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ZD4522 (5, 10, 20, 40 and 80 mg) in the Treatment of Subjects with Hypertriglyceridemia. 1999-2000
6. Principal Investigator: An Open-label, Multinational, Multicentre, Extension Trial to Assess the Long-term Safety and Efficacy of ZD4522 in Subjects in the ZD4522 Clinical Trial Program. 2000-2004
7. Subinvestigator: A Phase III Double-blind Efficacy and Safety Study of One Dose of SCH 58235 (10 mg) compared to Placebo in Subjects with Primary Hypercholesterolemia. 1999 – 2000
8. Principal Investigator: Long-Term, Open Label, Safety and Tolerability Study of SCH 58235 in Subjects with Primary Hypercholesterolemia. 2000 – 2002
9. Principal Investigator: CHARM - A randomized, double-blind, placebo-controlled parallel group, 6-week evaluation of cerivastatin 0.4 mg and atorvastatin 10 mg in post-menopausal women with hyperlipidemia and a 46-week evaluation in which cerivastatin 0.4 mg and cerivastatin 0.8 mg are compared to fenofibrate 201 mg for long-term lipid-lowering and bone mineral density effects. 1999 – 2001
10. Principal Investigator: A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment with Simvastatin 40 mg daily for 30 days, followed by Simvastatin 80 mg daily thereafter. 1999-2001
11. Principal Investigator: PROVE-IT – PRavastatin or AtorVastatin Evaluation and Infection Therapy. 2000 - 2003
12. Principal Investigator: BELLES - Beyond Endorsed Lipid Lowering with EBCT Scanning. 2000 - 2002
13. Principal Investigator: A Multicenter, Double-Blind, Randomized, Parallel, 12-Week, 4-Arm Study to Evaluate the Efficacy and Safety of L-654969 in Patients with Hypercholesterolemia (plus 48-week extension study) 2000 – 2003
14. Principal Investigator: A Double-Blind Comparison of 80 and 160 mg Doses of Pravastatin with Placebo in Hypercholesterolemic Subjects. 2000 – 2002
15. Principal Investigator: A Phase III Double-Blind Efficacy and Safety Study of SCH

58235 (10 mg) in Addition to Simvastatin in Subjects with Coronary Heart Disease or Multiple Risk Factors and with Primary Hypercholesterolemia Not Controlled by a Start Dose (20 mg) of Simvastatin. 2000 – 2002

16. Principal Investigator: A 6-week, Open-Label, Dose-comparison Study to Evaluate the Safety and Efficacy of Rosuvastatin Versus Atorvastatin, Cerivastatin, Pravastatin and Simvastatin in Subjects with Hypercholesterolemia. 2001 – 2004
17. Principal Investigator: CRISP - Cerivastatin Response and IL-6 and HS-CRP. 2001– 2002
18. Principal Investigator: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, “Factorial” Design, 12-Week Study to Evaluate the Efficacy of SCH 58235 10 mg/day Coadministered With Multiple Doses of Simvastatin in Patients with Primary Hypercholesterolemia. 2001 – 2003
19. Principal Investigator: NASDAC - A Multi-Center Eight Week Double Blind Assessment Comparing the Efficacy and Assessing the Safety of Atorvastatin at Starting Doses 10 mg, 20mg, 40 mg, and 80 mg. 2001 – 2002
20. Principal Investigator: MERCURY II - An Open-label, Randomized, Multi-center, Phase IIIb, Parallel Group Switching Study to Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin with Rosuvastatin in High Risk subjects with Type IIa and IIb Hypercholesterolemia. 2001 – 2004
21. Principal Investigator: A Comparison of Treatment with Ezetimibe (SCH-58235) and Simvastatin Co-administration Versus Simvastatin in Attaining the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Coronary Heart Disease (CHD) or CHD Risk Equivalent Strata LDL-C Target Level. 2002 – 2003
22. Principal Investigator: A 48-Week Open-Label, Non-Comparative, Multicentre, Phase IIIb Study to Evaluate the Efficacy and Safety of the Lipid-Regulating Agent Rosuvastatin in the Treatment of Subjects with Fredrickson Type IIa and Type IIb Dyslipidaemia, Including Heterozygous Familial Hypercholesterolemia. 2002 - 2004
23. Principal Investigator: A 6-week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolemia in South Asian Subjects. 2002 – 2005
24. Principal Investigator: JUPITER - A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of Rosuvastatin 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein. 2002 – 2008

25. Principal Investigator: Phase 3 multi-center, double-blind, randomized, parallel group, vascular B-mode ultrasound study of the anti-atherosclerotic efficacy, safety, and tolerability of fixed combination CP-529,414-atorvastatin, administered orally, one daily (QD) for 24 months, to subjects with mixed hyperlipidemia, compared with atorvastatin alone. 2003 –2006
26. Principal Investigator: A Phase II, Double-Blind, Randomized Placebo-controlled Parallel Group Study, Evaluating the Efficacy and Safety of Three Doses of RO4607381 Combined with Pravastatin over a 12 week period in Patients with Low or Average HDL-C levels. 2005 –2996
27. Principal Investigator: UNISON - A Double-Blind, Randomized STUDY TO Evaluate the Efficacy and Safety of TAK-475 50mg, 100mg, or Placebo when Co-Administered with Rosuvastatin 10mg or 20mg in Subjects with Primary Hypercholesterolemia. 2005 –2007
28. Principal Investigator: TEMPO - A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate and Compare the Efficacy and Safety of Eztemibe Added on to Atorvastatin 20mg Versus Up Titration to Atorvastatin 40mg in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease Not Adequately Controlled on Atorvastatin 20mg. 2006-2008

HYPERTENSION

1. Principal Investigator: A Triple-Blind, Parallel Study to Investigate the Effect of Losartan versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy. (LIFE) 1996-2001
2. Subinvestigator: A randomized, double-blind, placebo-controlled study to compare the effects of nabumetone (Relafen) 2 g per day, celecoxib (Celebrex) 400 mg per day and ibuprofen 2400 mg per day on blood pressure control in patients stabilized on antihypertensive therapy. 1999-2000
3. Principal Investigator: A Multicenter, Randomized, Double-Blind Placebo-Controlled, Parallel 13-week Study of Omapatrilat (BMS-186716) in Elderly Subjects with Mild to Moderate Hypertension. 1999-2002
4. Principal Investigator: Effects of Omapatrilat or Enalapril on Conduit Vessel Hemodynamics in Subjects with Systolic Hypertension. 2000 - 2001

5. Principal Investigator: A prospective, double-blind, randomized, parallel efficacy study of a losartan treatment regimen versus placebo in the treatment of patients with isolated systolic hypertension. 2000 - 2001
6. Principal Investigator: A Randomized, Double-Blind Safety and Efficacy Study of Losartan versus Losartan + Hydrochlorothiazide as First-Line therapy after 8 Weeks in Patients with Severe Hypertension. 2000 – 2002
7. Principal Investigator: OCTAVE - A Randomized, Double-Blind, Active-Controlled Comparison of Omapatrilat and Enalapril in Subjects with Newly Diagnosed or Established Hypertension. 2000 – 2002
8. Principal Investigator: A randomized, Double-Blind, Active-Controlled Evaluation of the Antihypertensive Response to Omapatrilat in Subjects Uncontrolled on Calcium-Channel Blocker Monotherapy. 2000 – 2001
9. Principal Investigator: A randomized, Double-Blind, Active-Controlled Evaluation of the Antihypertensive Response to Omapatrilat in Subjects Uncontrolled on ACE Inhibitor Monotherapy. 2000 – 2001
10. Principal Investigator: A Randomized, Double-Blind, Multicenter Study Comparing the Glycemic Control Characteristics of Carvedilol and Metoprolol in Hypertensive Patients with Type II Diabetes Mellitus. 2001 – 2003
11. Principal Investigator: AMAZE - Antihypertensive Efficacy of Adding Candesartan Cilexetil to Lisinopril in Comparison to Up-titration of Lisinopril, A Multi-Center Trial Using ATACAND-ZESTRIL vs. ZESTRIL to Evaluate the Effects on Lowering Blood Pressure. 2001 – 2002
12. Principal Investigator: A Randomized, Placebo-Controlled, Multicenter, Clinical Trial using 24-hour Blood Pressure Monitoring to Compare the Blood Pressure of Patients with Moderate Hypertension Receiving Lercanidipine 10 mg, 20 mg, 40 mg, Or Placebo. 2001 – 2003
13. Principal Investigator: RESPOND - A Prospective, Multi-Center Study Measuring the efficacy of a Fixed Combination of Therapy of Amlodipine and Atorvastatin to Treat Concurrent Hypertension and Hyperlipidemia to Desired Goals. 2001 - 2004
14. Principal Investigator: A double-blind, randomized, placebo and active controlled, parallel group, dose-finding study to evaluate the efficacy and safety of once daily oral administration of 5 mg, 10 mg, 25 mg, and 50 mg of M100240 for 8 weeks in subjects with mild-to-moderate essential hypertension. 2001 – 2003

15. Principal Investigator: A Randomized, Double-Blind, Safety and Efficacy Pilot Study of Losartan-Hydrochlorothiazide Versus Ramipril as First-Line Antihypertensive Therapy in Patients with Type 2 Diabetes Mellitus and Hypertension. 2002 – 2004
16. Principal Investigator: A Double-Blind, Randomized, Multi-Center, Active-Comparator, Five Treatment Study of The Effects of Nebivolol Compared to Atenolol on Cardiovascular Hemodynamics and Exercise Capacity in Patients with Mild to Moderate Hypertension. 2002 – 2003
17. Principal Investigator: A 12 month, randomized, open-label, multicenter, study to assess the long-term safety of aliskiren 150 mg alone and 300 mg alone or with the optional addition of hydrochlorothiazide (12.5 mg or 25 mg) in patients with essential hypertension. 2004 – 2007
18. Principal Investigator: CLEVER - A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG™ MR) and Atenolol in Combination with and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients with Left Ventricular Hypertrophy (LVH). 2006 – 2008
19. Principal Investigator: A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 with Valsartan in Subjects with Essential Hypertension
2007- 2008
20. Hyponatremia registry, current 2011- 2014
21. Principal Investigator, AVOID HF study, 2013- 2016

CARDIAC ARREST

1. Principal Investigator: CODE ARREST - Clinical Outcome after Sudden DEath in ARizona: A Retrospective cohort Evaluation STudy. 1998- 2001
2. **Principal Investigator: Public Access Defibrillation (PAD Trial). NIH sponsored study. 1999 – 2004**

CORONARY ARTERY DISEASE

1. Subinvestigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Comparison of Oral Viagra (Sildenafil Citrate) and Placebo to Assess the Exercise Time to the Onset of Limiting Angina During Treadmill Exercise in Male Subjects Who Have Erectile Dysfunction and Chronic Stable Angina. 1999-2000
2. Principal Investigator: A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCl vs Glyburide in the Treatment of Subjects with Type 2 (Non-Insulin Dependent) Diabetes Mellitus and Mild Cardiac Disease (NYHA I). 2001 – 2004
3. Principal Investigator: A Phase II, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled, Multicenter, Pharmacokinetic, Pharmacodynamic and Tolerability Study of ETC-642 in Patients with Stable Atherosclerosis. 2005
4. Principal Investigator: A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Who Are Medically Managed – The TRILOGY Study (2/6/08 – 2010)
5. Principal Investigator: A Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with Acute Coronary Syndrome: Thrombin Receptor Antagonist Syndrome (TRA-CER) (7-13-07 – 2012)
6. Principal Investigator: LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE (**LATITUDE**)-TIMI 60: 2014- 2016

PERIPHERAL VASCULAR DISEASE

1. Principal Investigator: A Multicenter, Double-blind, Randomized, Parallel Placebo-Controlled Study of the Safety and Efficacy of Chronic Oral Beraprost Sodium in Patients with Intermittent Claudication (Fontaine Stage II Peripheral Arterial Occlusive Disease). 2000 – 2003
2. Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm Study to Assess the Long-Term Effects of Pletal (Cilostazol) Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease. 2001 – 2005
3. Principal Investigator: ICPOP - The Effect of Niacin ER/Lovastatin on Peak Walking Time in Patients with Intermittent Claudication. 2002 – 2006

4. Principal Investigator: PROVIDENCE-I - Prospective, Randomized, Double-Blind (Phase 3) Study of Rifalazil Treatment on the Number of Vascular Interventions and Peripheral Vascular Disease Endpoints in *Chlamydia pneumoniae* Seropositive Patients. 2005 - 2007
5. Principal Investigator: TROPIC - The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients with Intermittent Claudication. 2005 – 2008
6. Principal Investigator: PACE - A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Study of the Effects of 6R-BH4 on Symptomatic Peripheral Arterial Disease. 2006- 2008

DIABETES / METABOLIC SYNDROME

1. Principal Investigator: A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HCl vs Glyburide in the Treatment of Subjects with Type 2 (Non-Insulin Dependent) Diabetes Mellitus and Mild Cardiac Disease (NYHA I) 2001 – 2003
2. Principal Investigator: A Multicenter, Double-Blind, Randomized, Active-Controlled Parallel Study in Patients with Type 2 Diabetes to Evaluate the Cardiac and Metabolic Effects of MK-0767. 2003
3. Principal Investigator: A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled Dose-Range Finding Study of L-000224715 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control. 2003 –2006
4. Principal Investigator: Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy. 2004 - 2007
5. Principal Investigator: A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 (50 mg qd or bid) to placebo as add-on therapy to glimepiride in patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. 2004 –2007
6. Principal Investigator: APPROACH - A Phase III, 18-month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare

Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 Diabetes Mellitus and Cardiovascular Disease. 2005 – 2006

7. Principal Investigator: A Multi-Center, Phase 3b, Stratified, Randomized, Open-Label, Clinical Trial to Evaluate the Efficacy of Intensive Apidra/Lantus Therapy Versus Sliding Scale Insulin on Infarct Size in Hyperglycemic Subjects with Anterior STEMI (ST Elevation Myocardial Infarction) Undergoing PCI (Percutaneous Coronary Intervention) INTENSIVE study 2009 -- 2011

MISCELLANEOUS

1. Principal Investigator: IMPACT - The Impact of Medical Subspecialty on Patient Compliance to Treatment. 2001 - 2002
2. Principal Investigator: ADONIS - American-Australian-African trial with DronedarONE in Atrial Fibrillation or flutter patients for the maintenance of Sinus rhythm. 2002 – 2003
3. Principal Investigator: Cardiac Output Comparison Using Impedance Cardiography and Thermodilution. 2005- 2007
4. Principal Investigator: AFFECTS - Atrial Fibrillation: Focus on Effective Clinical Treatment Strategies (Registry). 2005- 2008
5. Principal Investigator: ATHENA - A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess Efficacy of Dronedarone 400mg bid for Prevention of Cardiovascular Hospitalization or Death From Any Cause in patients with Atrial Fibrillation/Atrial Flutter (AF/AFL). 2005- 2009
6. Principal Investigator: BioZ DX Data Acquisition for Algorithm and Software Improvement. 2005- 2007
7. Principal Investigator: APPRAISE - A Phase 2, Placebo-Controlled, Randomized, Double-Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients with a Recent Acute Coronary Syndrome. 2006 – 2008
8. Principal Investigator: ZESCA - Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coronary Syndrome. 2006 – 2008
9. Principal Investigator: ATLAS - A Randomized, Double-Blind, Placebo-controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with Aspirin and a Thienopyridine in Subjects with Acute Coronary Syndromes: The ATLAS ACS TIMI 46 Trial. 2007 – 2008

10. Principal Investigator: ROCKET-AF - A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects with Non-Valvular Atrial Fibrillation. 2006 – 2010
11. Principal Investigator: ASPIRE – A 36-week, multi-center, randomized, double-blind, placebo controlled, parallel-group study to evaluate the efficacy and safety of aliskeren on prevention of left ventricular remodeling in high risk post-acute myocardial infarction patients when added to optimized standard therapy.2007-2009
12. Principal Investigator. Hyponatremia Registry, 2011- 2014
13. Principal Investigator, EPIC ER. Evaluation of patients with chest pain in the ER. 2012- 2014
14. Path to Wellness prevention project, sponsored by Dignity Health, 2013- 2015
15. The Himalayan Ladakh Cardiorenal screening Project, Aug 2013
16. ORBIT Registry for Atrial fibrillation, 2014- 2016
17. Principal Investigator, Clinical Protocol ZS-005, A Phase 3 Multicenter, Multi-dose, Open-label Maintenance Study to Investigate the Long-term Safety and Efficacy of ZS (Sodium Zirconium Cyclosilicate), an Oral Sorbent, in Subjects with Hyperkalemia, Including a Randomized, Double-blind, Placebo-controlled, Withdrawal Study; Dec 2014- 2016
18. Co- Principal Investigator, COAPT trial; Mitraclip in mitral regurgitation, Dec 2014- 2016
19. Principal investigator and Regional Principal Investigator, UPGRADE Registry: Pharmacogenomics testing, 2014- 2016
20. Co-Principal/Sub investigator, APOLLO INTREPID TMVR clinical Trial, 2017- current
21. Co- principal/sub-investigator. TRILUMINATE Evaluation of Treatment with Abbott Transcatheter Clip Repair System in Patients with Moderate or Greater Tricuspid Regurgitation (TRILUMINATE) (TRILUMINATE): 2019- current

INDEPENDENTLY GENERATED RESEARCH STUDIES

1. Preoperative Assessment of Predictors of Post Endoluminal Grafting Morbidity and Mortality.2001-2004
2. Effects of Statin in Post Intervention of Superficial femoral artery in Restenosis (STABILIZE) 2001-2003
3. American Association of Physicians of Indian origin: Diabetes in Indian Americans (AAPI - DIA) Project 2001-2004
4. Arizona Heart Institute and Veterans Administration Multiple Emerging Risk Factor Study in Atherosclerosis among Asian Indians (AHIMSA). 2003 – 2004 Completed. In Follow, up phase.
5. Predictors of Cardiovascular Postoperative Outcomes in Patients with Metabolic Syndrome. 2003 – 2004
6. Assessment of Effects of RV-sensed Triggered Biventricular Pacing mode on Metabolic Parameters in Patients with Congestive Heart Failure using BIOTRONIK CRT-D (ENSURE CRT) .2008- 2010
7. Research Grant from IBIS Foundation for Investigator initiated study: “Simplified Testing of miR-1: A Potential Biomarker for Cardiovascular Disease” May 5th, 2008. K. Vijayaraghavan and F. Zenhausen
8. Research grant from IBIS Foundation for investigator-initiated study: “Relation Between Molecular Properties & Cardiovascular Event Rate in People with Coronary Disease by Hemo-Nano-Rheology”. May 2008. F. Zenhausen and K. Vijayaraghavan
9. Project COMPASSION: Ongoing 2019- current.
<https://clinicaltrials.gov/ct2/show/NCT04905160?term=COMPASSION+in+CHF&draw=2&rank=1>
10. COROMEC .org Registry: Ongoing. 2019- current
<https://coromec.org/>
<https://clinicaltrials.gov/ct2/show/NCT04678193?term=COROMEC&draw=2&rank=1>
11. UPLIFT trial : Assessing feasibility of immersive technology in Life Simple & patient empowerment to improve outcomes. Ongoing

12. INSPIRIT : Assessing 30-day readmission with use of metaverse immersive technology as engagement intervention in Heart failure patients discharged from hospital. Ongoing
13. SAMARTH: Reducing maternal and infant mortality using immersive technology as interventional tool in midwives education in rural India. Ongoing

SENTINEL PUBLICATIONS:

1. Vijayaraghavan K, Crum S, Helgeson Q, Short term Intravenous Inotropes When Used as a Vehicle to Uptitrate Carvedilol Dosage in Class IV Congestive Heart Failure Patients Improves Ejection Fraction, Quality of Life and Survival. Sept 2001. J of Cardiac Failure, Vol 7, no.3, supp2, 80
2. Vijayaraghavan K, Mattioni T, Welch S, Ventricular Resynchronization Therapy Randomized Trial (VecTor): Chest. Nov 2001, Volume 120, page 245S
3. Vijayaraghavan K, Crum S, Barnett-Avery L, Chang P. Utility of Brain Natriuretic Peptide in Chronic Decompensated Heart Failure in an Outpatient Heart Failure Clinic. J of C Failure, volume 8, no 4, Aug 2002, 581
4. Vijayaraghavan K, Crum S, Helgeson Q, Barnett-Avery L, Chang P, Petchetti M, McPherson C. Improvement of Cardiac Outcomes in a Novel Heart Failure Program. J of C Failure, volume 8, no 4, Aug 2002, 581
5. Vijayaraghavan K, Crum S, Helgeson Q, Barnett-Avery L, Patchetti M, Chang P. Impedance Cardiography is a Useful Non-Invasive Modality in Management of Chronic Decompensated Heart Failure. Chest, Oct 2002, volume 122, no 4, 1705-1715
6. Vijayaraghavan K, Anemia as an important and independent risk factor in Heart Failure. Editorial commentary, National Anemia Action Council, www.anemia.org, Aug 8th, 2003
7. The PAD Trial Investigators, The Public Access Defibrillation Trial:

- Study Design and rationale, *Resuscitation*, 56, 2, 2003: 135-147
8. Groh W, Anton A, Vijayaraghavan K, Peberdy M, Slater B, Birnbaum A, Powell J, and the PAD Trial Investigators. Which Volunteers Respond to Cardiac Arrests: Results from the North American PAD Trial. *Circulation*, (Suppl) IV November 2003, 108, 17, 320.
 9. Christenson J, McNutt S, Shaum B, Vijayaraghavan K, Compton S, Slater B, Johnson S, McBurnie M, the PAD Trial Investigators. The effect of time between first and second retraining on CPR and Automated External Defibrillator (AED) skills in the Public Access Defibrillation (PAD) Trial. *Circulation* (suppl) IV November 2003, 108, 17, 321.
 10. Roberts R, Vijayaraghavan K, Adams K. Heart Failure and Anemia: An emerging health concern. Monograph published Feb 2004.
 11. Vijayaraghavan K, Santora L, Kahn J, Abbott N, Torelli J, Vardi G, and the ECP patient registry investigators. External counterpulsation therapy improves cardiac outcomes in chronic heart failure. *JACC*, vol 43, 5, suppl, 192
 12. Vijayaraghavan K, Crum S, Cherukuri S, Barnett-Avery L. Association of impedance cardiography parameters with changes in functional and quality of life measures in patients with chronic heart failure. *CHF* 2004; 10 (2 suppl 2): 17-21
 13. Sayre MR, Travers AH, Daya M, Greene HL, Salive ME, Vijayaraghavan K, Craven RA, Groh WJ, Hallstrom AP; PAD Investigators.. Measuring survival rates from cardiac arrest: The elusive definition. *Resuscitation* 62 (2004) 25-34.
 14. The Public Access Defibrillation Trial Investigators. Public-Access Defibrillation and Survival after Out-of-Hospital Cardiac Arrest. *N Engl J Med* 2004; 351:637-46.
 15. Vijayaraghavan K, Michota F. Optimizing Therapy for Acute Decompensated Heart Failure: An Evidence-Based Approach. American College of Chest Physicians *CME-Today* April 2004;

Volume 3, Issue 2: 7-17

16. **On companion CD: Case in Review: Optimally Managing Patients with Acute Decompensated Heart Failure: Optimizing Therapy for Acute Decompensated Heart Failure: An Evidence-Based Approach: CME-TODAY web workshop.**
17. Yancy CW, Saltzberg MT, Berkowitz RL, Bertolet B, Vijayaraghavan K, Burnham K, Oren RM, Walker K, Horton DP, Silver MA. Safety and Feasibility of Using Serial Infusions of *Nesiritide* for Heart Failure in an Outpatient Setting (from the FUSION I trial). *Am J Cardiol* 2004; 94:595-601.
18. Kris Vijayaraghavan, Michelle Jeffries, Mara Windsor, Anne Yost, Bridget Stiegler, Ned Williams, ACE Inhibitor Use Preoperatively Decreases Postoperative Complications in Patients with Metabolic Syndrome Undergoing Cardiothoracic or Vascular Interventions, *Chest* 2004 126: 711S-a
19. Krishnaswami Vijayaraghavan, Sue Crum, Michelle Jeffries. Leslie Barnett-Avery. Prevalence of Anemia and Other Co-Morbid Conditions in Patients with Severe Heart Failure in an Outpatient Heart Failure Clinic. (*Can J Card*, Oct 2004)
20. Kris Vijayaraghavan, Ranjita Misra, Peter Reaven, Michelle Jeffries, Vicky Camacho, Krishnankutty Sudhir, Mathew Budoff, Body Mass Index is a significant predictor of atherosclerosis as detected by Electron Beam Tomography in Asian Indians: Arizona Heart Institute Multiple Emerging Risk Factor Assessment of Atherosclerosis among Asian Indians (AHIMSA) Study. *Diabetes*, June 2005, 2239-PO
21. Kris Vijayaraghavan, Ranjita Misra, Peter Reaven, Michelle Jeffries, Vicky Camacho, Krishnankutty Sudhir, Lipoprotein Associated Phospholipase A₂ (LpPLA₂) is Significantly Associated with Carotid Intimal Medial Thickness in Asian Indian Population: Arizona Heart Institute Multiple Emerging Risk Factor aSessment of

Atherosclerosis Among Asian Indians (AHIMSA) Study (J of Am Col Card, Feb 1, 2005; vol 45, no 3,422A)

- 22. Vijayaraghavan K, Deedwania PC. The renin angiotensin system as a therapeutic target to prevent diabetes and its complications. Cardiol Clin (2005) 165-183**
- 23. Vijayaraghavan K, Santora L, Kahn J, Abbott N, Torelli J, Vardi G: New graduated pressure regimen for external counterpulsation reduces mortality and improves outcomes in congestive heart failure: a report from the Cardiomedics External Counterpulsation Patient Registry.. (CHF.2005;11:147-152)**
- 24. K. Vijayaraghavan, Barnet-Avery, L, Eike, S, et al: Anemia precludes use of beta blockers in patients with Chronic Heart Failure. CHEST, 130, 4: 193S-194S**
- 25. Chiong JR, Aronow WS, Khan IA, Nair CK, Vijayaraghavan K, Dart RA, Behrenbeck TR, Geraci SA. Secondary hypertension: Current diagnosis and treatment. Int J Cardiol. 2007 Apr 25; [Epub ahead of print]**
- 26. Groh WJ, Birnbaum A, Barry A, Anton A, Mann NC, Peberdy MA, Vijayaraghavan K, Powell J, Mosesso VN Jr; PAD Trial Investigators. Characteristics of volunteers responding to emergencies in the Public Access Defibrillation Trial. Resuscitation. 2007 Feb;72(2):193-9. Epub 2006 Nov 22.**
- 27. Christenson J, Nafziger S, Compton S, Vijayaraghavan K, Slater B, Ledingham R, Powell J, McBurnie MA; PAD Investigators the PAD Investigators. The effect of time on CPR and automated external defibrillator skills in the Public Access Defibrillation Trial. Resuscitation 2007 Jul;74(1):52-62. Epub 2007 Feb 14, 2007**
- 28. Krishnaswami Vijayaraghavan, V. Camacho, M Jeffries, M Budoff, R Misra, E Brinton. Gender differences in Insulin resistance among Asian Indians. Atherosclerosis in Asian Indians: Multiple Risk Factor Study Assessment (AHIMSA). JACC, Mar 6th, 2007. 379 A; 1020-12. ONLINE version: doi: 10.1016/j.jacc.2007.01.043**
- 29. Douglas PS, Khandheria B, Stainback RF, Weissman NJ, Brindis RG, Patel MR, Khandheria B, Alpert JS, Fitzgerald D, Heidenreich P, Martin ET, Messer JV,**

Miller AB, Picard MH, Raggi P, Reed KD, Rumsfeld JS, Steimle AE, Tonkovic R, Vijayaraghavan K, Weissman NJ, Yeon SB, Brindis RG, Douglas PS, Hendel RC, Patel MR, Peterson E, Wolk MJ, Allen JM; American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group; American Society of Echocardiography; American College of Emergency Physicians; American Society of Nuclear Cardiology; Society for Cardiovascular Angiography and Interventions; Society of Cardiovascular Computed Tomography; Society for Cardiovascular Magnetic Resonance; American College of Chest Physicians; Society of Critical Care Medicine. ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance endorsed by the American College of Chest Physicians and the society of critical care medicine. *J Am Coll Cardiol.* 2007 Jul 10;50(2):187-204.

30. TTE/TEE Appropriateness Criteria Writing Group, Douglas PS, Khandheria B, Stainback RF, Weissman NJ; TTE/TEE Appropriateness Criteria Technical Panel, Brindis RG, Patel MR, Alpert JS, Fitzgerald D, Heidenreich P, Martin ET, Messer JV, Miller AB, Picard MH, Raggi P, Reed KD, Rumsfeld JS, Steimle AE, Tonkovic R, Vijayaraghavan K, Yeon SB; ACCF Appropriateness Criteria Working Group, Hendel RC, Peterson E, Wolk MJ, Allen JM; American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group; American Society of Echocardiography; American College of Emergency Physicians; American Society of Nuclear Cardiology; Society for Cardiovascular Angiography and Interventions; Society of Cardiovascular Computed Tomography; Society for Cardiovascular Magnetic Resonance.

ACCF/ASE/ACEP/ASNC/SCAI/SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American Society of Echocardiography, American College of Emergency Physicians, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society for Cardiovascular Magnetic Resonance. Endorsed by the American College of Chest Physicians and the Society of Critical Care Medicine. J Am Soc Echocardiogr. 2007 Jul;20(7):787-805.

- 31. Vijayaraghavan K, Prakash C. Deedwania; Blockage of Renin Angiotensin System on Metabolic Syndrome: Implications for prevention of Diabetes (chapter in a Textbook: Therapeutic Strategies in Metabolic Syndrome, editor, Dr Vivian Fonseca), Oxford Press, 2008**
- 32. Yancy CW, Krum H, Massie BM, Silver MA, Stevenson LW, Cheng M, Kim SS, Evans R; FUSION II Investigators. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. Circ Heart Fail. 2008 May;1(1):9-16. doi: 10.1161/CIRCHEARTFAILURE.108.767483.**
- 33. Whellan DJ, O'Connor CM, Ousdigian KT, Lung TH; PARTNERS HF Study Investigators. Rationale, design, and baseline characteristics of a Program to Assess and Review Trending Information and Evaluate Correlation to Symptoms in Patients with Heart Failure (PARTNERS HF). Am Heart J. 2008 Nov;156(5):833-9, 839.e2. doi: 10.1016/j.ahj.2008.06.036. Epub 2008 Sep 23.**
- 34. Vijayaraghavan K and Deedwania PC. Special Patient Populations: Lipid Abnormalities in High-Risk Ethnic Groups. In: Ballantyne CM, Ed. Clinical Lipidology: A Companion to Braunwald's Heart Disease. Philadelphia: Saunders, 2009, pp. 509-518.**
- 35. Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, Joshi SR, Sadikot S, Gupta R, Gulati S, Munjal YP; Concensus Group.: Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic**

syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. *J Assoc Physicians India*. 2009 Feb; 57:163-70.

36. Prevalence of diabetes, metabolic syndrome, and cardiovascular risk factors in US Asian Indians: results from a national study. Misra R, Patel T, Kotha P, Raji A, Ganda O, Banerji M, Shah V, Vijay K, Mudaliar S, Iyer D, Balasubramanyam A. *J Diabetes Complications*. 2009 Mar 18. [Epub ahead of print]
37. Ranjita Misra, Thakor Patel, Purushotham Kotha, Annaswamy Raji, Om Ganda, MaryAnn Banerji, Viral Shah, Kris Vijay, Sundar Mudaliar, Dinakar Iyer, Ashok Balasubramanyam. Prevalence of diabetes, metabolic syndrome, and cardiovascular risk factors in US Asian Indians: results from a national study. *Journal of Diabetes and its Complications*. Volume 24, Issue 3, Pages 145-153 (May-June 2010)
38. Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW; APPROACH Study Group. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. *Circulation*. 2010 mar 16;121(10):1176-87. doi: 10.1161/CIRCULATIONAHA.109.881003. Epub 2010 Mar 1.
39. Vijayaraghavan K. Treatment of dyslipidemia in patients with type 2 diabetes. *Lipids Health Dis*. 2010 Dec 20; 9(1):144.
40. ACCF/AHA/ASA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society

for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians. Douglas PS, Garcia MJ, et al. *J Am Coll Cardiol*. 2011 Mar 1;57(9):1126-66. No abstract available.

<http://content.onlinejacc.org/cgi/content/full/j.jacc.2010.11.002>

41. Yancy CW, Wang TY, Ventura HO, Piña IL, Vijayaraghavan K, Ferdinand KC, Hall LL; credo Advisory Group. The Coalition to Reduce Racial and Ethnic Disparities in Cardiovascular Disease Outcomes (credo) Why credo Matters to Cardiologists. *J Am Coll Cardiol*. 2011 Jan 18;57(3):245-52. PMID: 21232662 [PubMed - in process]. see link:
<http://content.onlinejacc.org/content/vol57/issue3/index.dtl>
42. Krishnaswami Vijayaraghavan, Deedwania. Renin-Angiotensin-Aldosterone Blockade for Cardiovascular Disease Prevention, *Cardiology Clinics*, Volume 29, Issue 1, Pages 137-156,
43. Cedric Hurth, Katherine Klein, Lena van Nimwegen, Ronald Korn, Krishnaswami Vijayaraghavan, and Frederic Zenhausem, Clinical diagnostic of pleural effusions using a high-speed viscosity measurement method, *J. Appl. Phys.* 110, 034701 (2011); doi:10.1063/1.3615964
44. Enas E, Pazhoor, HC, Kuruvilla A, Vijayaraghavan K. Intensive statin treatment for Indians: part I Benefits. *Indian Heart J*. 2011; 63:211-227
45. K. Vijayaraghavan. Coronary Artery Disease: Demographics and prevalence. McGraw Hill specialty Board Review. *Cardiology*. 2012. Pages 291-304
46. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. *N Engl J Med*. 2012 Jan 5;366(1):20-33. doi: 10.1056/NEJMoa1109719. Epub 2011 Nov 13.
47. Kris Vijay. Lipid abnormalities in South Asians living in the USA. *J. Preventive*

Cardiology N Vol. 1 n No. 4 n May 2012 173 – 175

48. Misra A, Nigam P, Hills AP, Chadha DS, Sharma V, Deepak KK, Vikram NK, Joshi S, Chauhan A, Khanna K, Sharma R, Mittal K, Passi SJ, Seth V, Puri S, Devi R, Dubey AP, Gupta S; Physical Activity Consensus Group. Consensus physical activity guidelines for Asian Indians. *Diabetes Technol Ther.* 2012 Jan;14(1):83-98. doi: 10.1089/dia.2011.0111. Epub 2011 Oct 11.
49. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T; REVIVE Heart Failure Study Group. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. *JACC Heart Fail.* 2013 Apr;1(2):103-11. doi: 10.1016/j.jchf.2012.12.004. Epub 2013 Apr 1
50. 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: a joint report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate Use Criteria Task Force. Patel MR, White RD, Abbara S, Bluemke DA, Herfkens RJ, Picard M, Shaw LJ, Silver M, Stillman AE, Udelson J; American College of Radiology Appropriateness Criteria Committee; American College of Cardiology Foundation Appropriate Use Criteria Task Force. *J Am Coll Cardiol.* 2013 May 28;61(21):2207-31. doi: 10.1016/j.jacc.2013.02.005. Epub 2013 Apr 23
51. Kolte D, Vijayaraghavan K, Khera S, Sica DA, Frishman WH. Role of magnesium in cardiovascular diseases. *Cardiol Rev.* 2014 Jul-Aug;22(4):182-92.
52. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA; ROCKET AF Steering Committee and Investigators. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). *Circulation.* 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. Epub 2014 Jun 3. Erratum in: *Circulation.* 2018 Dec 18;138(25):e783. PMID: 24895454.
53. 2nd Annual Convention of the Cardio Renal Society of America: Cardio Renal

Crisis: Global Epidemiology. Scottsdale, Ariz., March 8, 2014: Abstracts;
Cardiorenal Med 2014;4:140-145 (DOI: 10.1159/000365644)
<http://www.karger.com/DOI/10.1159/000365644>

54. Nair N, Gupta S, Collier E, Gongora I, Vijayaraghavan K. Can microRNAs emerge as biomarkers in distinguishing HFpEF versus HFrEF?, *Int J Cardiol* (2014), <http://dx.doi.org/10.1016/j.ijcard.2014.06.027>
55. Lipid abnormalities in high-risk ethnic populations: Braunwald's companion to *Clinical Lipidology*, 2014: Chapter 42; 490- 503
56. Clinical Feature; Triglyceride Enigma: lipid Spin, Winter Edition, 2014: <https://www.lipid.org/node/1325>
57. Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després JP, Ndumele CE, Vijayaraghavan K, et al. The Cardiometabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome, *J Am Coll Cardiol*. 2015 Sep 1; 66(9):1050-67. doi: 10.1016/j.jacc.2015.06.1328.
58. Jacobson TA, Maki KC, Orringer C, Jones P, Kris-Etherton P, Sikand G, Forge RL, Daniels S, Wilson D, Morris P, Wild R, Grundy S, Daviglius M, Ferdinand K, Vijayaraghavan K, Deedwania P, Aberg J, Liao K, McKenney J, Ross J, Braun L, Ito M, Bolick J, Dicklin MR, Kirkpatrick C, Rhodes K, Smith NT, Blackett P, DeFerranti S, Gidding S, Kavey R-EW, McCrindle B, McNeal C, Urbina E, Dayspring T, Underberg JA, Lopez JAG, Pirzada A, Rodriguez CJ, Fichtenbaum CJ, Gallant JE, Horberg MA, Longenecker CT, Myerson M, Overton ET, Coblyn JS, Curtis J, Plutzky J, Solomon D, Bays H, Brown WV, National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2, *Journal of Clinical Lipidology* (2015), doi: 10.1016/j.jacl.2015.09.002.
59. McCullough PA, Tumlin JA, Szerlip H, Vijayaraghavan K, Jyothinagaram S, et al. (2015) Cardiorenal Syndromes: Advances in Determining Diagnosis, Prognosis, and Therapy. *J Cardiovasc Dis Diagn* 3:221. doi: 10.4172/2329-9517.1000221
60. Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee & Investigators; ROCKET AF Steering Committee Investigators. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. *J Am Heart Assoc*. 2016 Mar 8;5(3):e002197. doi: 10.1161/JAHA.115.002197. PMID: 26955859; PMCID: PMC4943233.

61. K. Vijayaraghavan, Guest Editorial: Collaboration and Teamwork, Lipid Spin, 2017, <https://www.lipid.org/node/2108>
62. K. Vijayaraghavan, Pradeep Bhat, Novel biomarkers in cardiorenal syndrome. Handbook of Coronary Artery Disease, 2017. Chapter 17, Pages 191: 200
63. Abstract 15097: Icosapent Ethyl Reduces Potentially Atherogenic Lipid and Inflammatory Markers in High-Risk Statin-Treated Patients with Stage 3 chronic kidney disease and Persistent High Triglycerides, Krishnaswami Vijayaraghavan, Harold M Szerlip, Christie M Ballantyne, Harold E Bays, Sephy Philip, Ralph T Doyle, Rebecca A Juliano and Craig Granowitz, Circulation. 2017;136: A15097, originally published November 11, 2017
64. Kenneth M. Borow, R. Preston Mason, Krishnaswami Vijayaraghavan. Eicosapentaenoic Acid as a Potential Therapeutic Approach to Reduce Cardiovascular Risk in Patients with End-Stage Renal Disease on Hemodialysis: A Review; Cardiorenal Med 2018; 8:18–30
65. Vijayaraghavan K. · McCullough P.A. · Singh B. · Gupta M. · Enas E. · Mohan V. · Misra A. · Deedwania P. · Brinton E.A. for the Consensus Panel Steering Committee Cardiometabolic-Renal Disease in South Asians: Consensus Recommendations from the Cardio Renal Society of America, cardiorenal medicine 2019;9:240-251, <http://doi.org/10.1159/000499341>
66. Vijayaraghavan, K, Brown, A, South Asian ancestry as a risk enhancer for ASCVD: Merits and challenges <https://doi.org/10.1016/j.jacl.2019.04.009>
67. <https://www.healio.com/cardiology/chd-prevention/news/online/%7Bee9e0a57-84cf-44c2-ae5d-97c11b56354f%7D/south-asians-have-an-increased-risk-for-chd-events-diabetes>
68. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference, Open Access, Kidney international, DOI: <https://doi.org/10.1016/j.kint.2019.02.022>
69. Krishnaswami Vijayaraghavan, Harold M. Szerlip, Christie M. Ballantyne, Harold E. Bays, Sephy Philip, Ralph T. Doyle Jr, Rebecca A. Juliano & Craig Granowitz, (2019): Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides, Postgraduate Medicine, DOI: 10.1080/00325481.2019.1643633
70. Muruganathan, A.¹; Rader, Florian²; Blyler, Ciantel²; Vijayaraghavan, Krishnaswami³; Maheshwari, Anuj⁴; Verma, Narsingh⁵; Mubarak, Mr⁶; Das, Mk⁷; Mohanan, Pp⁸; Mishra, Sundeep⁹; Mehta, Ashwani¹⁰ SUSTAINABILITY OF BLOOD PRESSURE REDUCTIONS AT INTERVENTIONS LED AT BARBERSHOPS: SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS, Journal of Hypertension: April 2021 -

71. Nambi V, Sikand G, Kalra D, Vijayaraghavan K. Low-density lipoprotein cholesterol goals in the secondary prevention of cardiovascular diseases in the Indian population-Is 30 the new 70? *J Clin Lipidol*. 2020 Jan 30. pii: S1933-2874(20)30011-8. doi: 10.1016/j.jacl.2020.01.011. [Epub ahead of print] No abstract available. PMID:32098725
72. McCullough, Eidt, Vijay, et al. Urgent need for individual mobile phone and institutional reporting of at home, hospitalized, and intensive care unit cases of SARS-CoV-2 (COVID-19) infection, *Reviews in Cardiovascular medicine*, 2020 21 (1): 1-7 ISSN: 2153-8174 CN
73. Kalra D, Sikand G, Vijayaraghavan K, Guyton J. JCL Round Table: South Asian atherosclerotic risk. *Clinical Lipidology Roundtable Discussion*. Vol 14, Issue 2, p161-169, March 01, 2020. DOI: <https://doi.org/10.1016/j.jacl.2020.03.00>
74. Krishnaswami Vijayaraghavan, Desiree Little, Tamera Querrey, Teresa Mercer, Cesar Delgado, Gopi Cherukuri, Aye Win, Timothy Byrne, Inspire - HF Manifesto Reduces Readmissions And Improves Outcomes In Chronic Heart Failure, *Journal of Cardiac Failure*, Volume 26, Issue 10, Supplement, 2020, Page S47, ISSN 1071-9164, <https://doi.org/10.1016/j.cardfail.2020.09.137>.
(<http://www.sciencedirect.com/science/article/pii/S1071916420310848>)
75. Krishnaswami Vijayaraghavan, Desiree Little, Teresa Mercer, Tamera Querrey, Sarah Wilmowski, Aye Win, Gopi Cherukuri, Timothy Byrne, Midodrine As A Bridge To Enable Use of Life Enhancing Therapies In Chronic Heart Failure, *Journal of Cardiac Failure*, Volume 26, Issue 10, Supplement, 2020, Page S59, ISSN 1071-9164, <https://doi.org/10.1016/j.cardfail.2020.09.175>.
(<http://www.sciencedirect.com/science/article/pii/S1071916420311222>)
76. Peter A. McCullough, Ronan J. Kelly, Gaetano Ruocco, Edgar Lerma, James Tumlin, Kevin R. Wheelan, Nevin Katz, Norman E. Lepor, Kris Vijay, Harvey Carter, Bhupinder Singh, Sean P. McCullough, Brijesh K. Bhambi, Alberto Palazzuoli, Gaetano M. De Ferrari, Gregory P. Milligan, Taimur Safder, Kristen M. Tecson, Dee Dee Wang, John E. McKinnon, William W. O'Neill, Marcus Zervos, Harvey A. Risch, Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection, *The American Journal of Medicine*, 2020, ISSN 0002-9343,
<https://doi.org/10.1016/j.amjmed.2020.07.003>.
(<http://www.sciencedirect.com/science/article/pii/S0002934320306732>)
77. Bradley Williams, MD, Mehak Aggarwal, PharmD, Cole Kiser, Krishnaswami Vijayaraghavan, Enhanced External Counterpulsation Reduces Blood

Pressure in Patients with Chronic Stable Angina: A Meta-Analysis, Sachin A. Shah, PharmD, FACC, FAHA. Accepted for publication, Circulation, November, 2020.

- 78. Vijayaraghavan, K, Kalra, D. Clinical Feature: The Unique South Asian Phenotype and Opportunities for Early Intervention to Prevent Diabetes and ASCVD. Lipid Spin Spring 2020**
- 79. Puri R, Mehta V, Iyengar SS, Narasingan SN, Duell PB, Sattur GB, Vijayaraghavan K, Mohan JC, Wangnoo SK, Dalal J, Prabhakar D, Agarwal R, Bansal M, Yusuf J, Mukhopadhyay S, Shetty S, Manoria PC, Sabharwal A, Pradhan A, Mehrotra R, Mishra S, Puri S, Muruganathan A, Zargar AH, Patanwala RM, Kumar S, Bardoloi N, Pareek KK, Kapoor A, Rastogi A, Nair DR, Shaikh A, Adhikari CM, Majumder MSM, Kapoor D, Yadav M, Mubarak MR, Pancholia AK, Sahay RK, Nanda R, Wong ND. Non-HDL Cholesterol and Atherosclerotic Cardiovascular Disease. J Assoc Physicians India. 2020 Nov;68(11[Special]):54-58. PMID: 33350617.**
- 80. Puri R, Mehta V, Iyengar SS, Narasingan SN, Duell PB, Sattur GB, Vijayaraghavan K, Mohan JC, Wangnoo SK, Dalal J, Prabhakar D, Agarwal R, Bansal M, Yusuf J, Mukhopadhyay S, Shetty S, Manoria PC, Sabharwal A, Pradhan A, Mehrotra R, Mishra S, Puri S, Muruganathan A, Zargar AH, Patanwala RM, Kumar S, Bardoloi N, Pareek KK, Kapoor A, Rastogi A, Nair DR, Shaikh A, Adhikari CM, Majumder MSM, Kapoor D, Yadav M, Mubarak MR, Pancholia AK, Sahay RK, Nanda R, Wong ND. Apolipoprotein B as a Predictor of CVD. J Assoc Physicians India. 2020 Nov;68(11[Special]):50-53. PMID: 33350616.**
- 81. Puri R, Mehta V, Iyengar SS, Narasingan SN, Duell PB, Sattur GB, Vijayaraghavan K, Mohan JC, Wangnoo SK, Dalal J, Prabhakar D, Agarwal R, Bansal M, Yusuf J, Mukhopadhyay S, Shetty S, Manoria PC, Sabharwal A, Pradhan A, Mehrotra R, Mishra S, Puri S, Muruganathan A, Zargar AH, Patanwala RM, Kumar S, Bardoloi N, Pareek KK, Kapoor A, Rastogi A, Nair DR, Shaikh A, Adhikari CM, Majumder MSM, Kapoor D, Yadav M, Mubarak MR, Pancholia AK, Sahay RK, Nanda R, Wong ND. High Sensitivity C-Reactive Protein. J Assoc Physicians India. 2020 Nov;68(11[Special]):47-49. PMID: 33350615.**
- 82. Puri R, Mehta V, Iyengar SS, Narasingan SN, Duell PB, Sattur GB, Vijayaraghavan K, Mohan JC, Wangnoo SK, Dalal J, Prabhakar D, Agarwal R, Bansal M, Yusuf J, Mukhopadhyay S, Shetty S, Manoria PC, Sabharwal A, Pradhan A, Mehrotra R, Mishra S, Puri S, Muruganathan A, Zargar AH, Patanwala RM, Kumar S, Bardoloi N, Pareek KK, Kapoor A, Rastogi A, Nair DR, Shaikh A, Adhikari CM, Majumder MSM, Kapoor D, Yadav M, Mubarak MR, Pancholia AK, Sahay RK, Nanda R, Wong ND. Lipoprotein(a) and ASCVD risk. J Assoc Physicians India. 2020 Nov;68(11[Special]):42-46. PMID: 33350614.**

83. Puri R, Mehta V, Iyengar SS, Narasingan SN, Duell PB, Sattur GB, Vijayaraghavan K, Mohan JC, Wangnoo SK, Dalal J, Prabhakar D, Agarwal R, Bansal M, Yusuf J, Mukhopadhyay S, Shetty S, Manoria PC, Sabharwal A, Pradhan A, Mehrotra R, Mishra S, Puri S, Muruganathan A, Zargar AH, Patanwala RM, Kumar S, Bardoloi N, Pareek KK, Kapoor A, Rastogi A, Nair DR, Shaikh A, Adhikari CM, Majumder MSM, Kapoor D, Yadav M, Mubarak MR, Pancholia AK, Sahay RK, Nanda R, Wong ND. Triglycerides and Atherosclerotic Cardiovascular Disease. *J Assoc Physicians India*. 2020 Nov;68(11[Special]):35-41. PMID: 33350613.
84. Puri R, Mehta V, Iyengar SS, Narasingan SN, Duell PB, Sattur GB, Vijayaraghavan K, Mohan JC, Wangnoo SK, Dalal J, Prabhakar D, Agarwal R, Bansal M, Yusuf J, Mukhopadhyay S, Shetty S, Manoria PC, Sabharwal A, Pradhan A, Mehrotra R, Mishra S, Puri S, Muruganathan A, Zargar AH, Patanwala RM, Kumar S, Bardoloi N, Pareek KK, Kapoor A, Rastogi A, Nair DR, Shaikh A, Adhikari CM, Majumder MSM, Kapoor D, Yadav M, Mubarak MR, Pancholia AK, Sahay RK, Nanda R, Wong ND. Low Density Lipoprotein Cholesterol Targets in Secondary Prevention of Atherosclerotic Cardiovascular Disease. *J Assoc Physicians India*. 2020 Nov;68(11[Special]):21-34. PMID: 33350612.
85. Puri R, Mehta V, Iyengar SS, Narasingan SN, Duell PB, Sattur GB, Vijayaraghavan K, Mohan JC, Wangnoo SK, Dalal J, Prabhakar D, Agarwal R, Bansal M, Yusuf J, Mukhopadhyay S, Shetty S, Manoria PC, Sabharwal A, Pradhan A, Mehrotra R, Mishra S, Puri S, Muruganathan A, Zargar AH, Patanwala RM, Kumar S, Bardoloi N, Pareek KK, Kapoor A, Rastogi A, Nair DR, Shaikh A, Adhikari CM, Majumder MSM, Kapoor D, Yadav M, Mubarak MR, Pancholia AK, Sahay RK, Nanda R, Wong ND. Lifestyle Modification in the Prevention of Atherosclerotic Cardiovascular Disease. *J Assoc Physicians India*. 2020 Nov;68(11[Special]):10-20. PMID: 33350611.
86. Puri R, Mehta V, Iyengar SS, Narasingan SN, Duell PB, Sattur GB, Vijayaraghavan K, Mohan JC, Wangnoo SK, Dalal J, Prabhakar D, Agarwal R, Bansal M, Yusuf J, Mukhopadhyay S, Shetty S, Manoria PC, Sabharwal A, Pradhan A, Mehrotra R, Mishra S, Puri S, Muruganathan A, Zargar AH, Patanwala RM, Kumar S, Bardoloi N, Pareek KK, Kapoor A, Rastogi A, Nair DR, Shaikh A, Adhikari CM, Majumder MSM, Kapoor D, Yadav M, Mubarak MR, Pancholia AK, Sahay RK, Nanda R, Wong ND. Lipid Association of India Expert Consensus Statement on Management of Dyslipidemia in Indians 2020: Part III. *J Assoc Physicians India*. 2020 Nov;68(11[Special]):8-9. PMID: 33350610.
87. McCullough PA, Vijay K. SARS-CoV-2 infection and the COVID-19 pandemic: a call to action for therapy and interventions to resolve the crisis of hospitalization, death, and handle the aftermath. *Rev Cardiovasc Med*. 2021 Mar 30;22(1):9-10. doi: 10.31083/j.rcm.2021.01.301. PMID: 33792243.

88. Kalra D, Vijayaraghavan K, Sikand G, Desai NR, Joshi PH, Mehta A, Karmally W, Vani A, Sitafalwalla SJ, Puri R, Duell PB, Brown A. Prevention of atherosclerotic cardiovascular disease in South Asians in the US: A clinical perspective from the National Lipid Association. *J Clin Lipidol*. 2021 May-Jun;15(3):402-422. doi: 10.1016/j.jacl.2021.03.007. Epub 2021 Mar 29. PMID: 33846108.
89. Vijay K, Neuen B, Lerma E. When Heart Failure Collides with Diabetes and Chronic Kidney Disease: Challenges and Opportunities. *Cardiorenal Med*. 2021 Nov 19. doi: 10.1159/000520909. Epub ahead of print. PMID: 34802000.
90. Member spotlight Diversity, Equity, and Inclusion. <https://www.lipid.org/lipid-spin/winter-2021-2022/member-spotlight-dei-spotlight>
91. Puri R, Mehta V, Duell PB, Iyengar SS, Yusuf J, Dalal J, Narasingan SN, Kalra D, Kapoor A, Pradhan A, Mukhopadhyay S, Vijayaraghavan K, Aggarwal R, Muruganathan A, Prabhakar D, Misra S, Shetty S, Kasliwal RR, Bansal M, Khanna N, Khan A, Melinker RP, Kumar S, Chakraborty RN, Bardoloi N, Sahoo P, Vinayagam P, Modi R, Nanda R, Wong ND. Evidence for intensive LDL-C lowering for acute coronary syndrome: Recommendations from the Lipid Association of India. *J Clin Lipidol*. 2022 Mar 25:S1933-2874(22)00066-6. doi: 10.1016/j.jacl.2022.03.008. Epub ahead of print. PMID: 35508456.
92. UPLIFT clinical Trial : evalUation of imPact of a novel immersive technology in patient engagement of LIFe simple 7 to prevent risk of hearT disease: UPLIFT clinical Trial, Michael Castro, Aditya Vijay, Navin Govind, Moh Barathan, Leticia Medina, Aravind Upadhyaya, Krishnaswami Vijayaraghavan ,Arrowhead Internal Medicine, University of Arizona. Presented at Cardiometabolic Health Congress, Boston USA, Oct 2022.
93. Frederick Berro Rivera, Vincent Anthony S. Tang, Deogracias Villa De Luna, Edgar V. Lerma, Krishnaswami Vijayaraghavan, Amir Kazory, Nilay S. Shah, Annabelle Santos Volgman, Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis, *American Heart Journal Plus: Cardiology Research and Practice*, Volume 26,2023,100261, ISSN 2666-6022, <https://doi.org/10.1016/j.ahjo.2023.100261>.
94. Rivera F, DeLuna D, Vijayaraghavan K, et al. Transcatheter Aortic Valve Implantation Outcomes and Challenges in Asia: A Systematic Review and Meta-analysis. Accepted as abstract , ACC, Presentation in March 2023,

New Orleans.

95. Frederick Berro Rivera, Deogracias Villa De Luna, Marie Francesca Mapua Ansay, Ryan T. Nguyen, Gabrielle Pagdilao Flores, John Vincent Magalong, Sung Whoy Cha, John Paul Aparece, Jacques Simon T. Gonzales, Wailea Faye C. Salva, Gerard Francis E. Mangubat, Mer Lorraine P. Mahilum, Taku Inohara, Krishnaswami Vijayaraghavan, Fareed Moses S. Collado, Azeem Latib. Transcatheter Aortic Valve Implantation Outcomes and Challenges in Asia: A Systematic Review and Meta-Analysis. *Rev. Cardiovasc. Med.* 2023, 24(3), 79. <https://doi.org/10.31083/j.rcm2403079>
96. Frederick Berro Rivera, Marianne Katharina Taliño, Marie Francesca Ansay, Gerard Francis Mangubat, Mer Lorraine Mahilum, Rajiv Hans Menghrajani, Siena Placino, Sung Whoy Cha, John Paul Aparece, Marc Gregory Yu, Michael Lawrenz Co, Edgar Lerma, Krishnaswami Vijayaraghavan, Peter A. McCullough. Cardiovascular Effects of Excess Growth Hormone: How Real is the Threat?. *Rev. Cardiovasc. Med.* 2023, 24(4), 95. <https://doi.org/10.31083/j.rcm2404095>
97. Velarde G, Bravo-Jaimes K, Brandt EJ, Wang D, Douglass P, Castellanos LR, Rodriguez F, Palaniappan L, Ibebuogu U, Bond R, Ferdinand K, Lundberg G, Thaman R, Vijayaraghavan K, Watson K. Locking the Revolving Door: Racial Disparities in Cardiovascular Disease. *J Am Heart Assoc.* 2023 Mar 21:e025271. doi: 10.1161/JAHA.122.025271. Epub ahead of print. PMID: 36942617.
98. Brandt, Eric, Tobb, Kardie, Watson, Karol, Vijayaraghavan, K, et al. Assessing and Addressing Social Determinants of Health *J Am Coll Cardiol.* 2023 Apr, 81 (14) 1368–1385. <https://doi.org/10.1016/j.jacc.2023.01.042>
99. UPLIFT clinical Trial : evaluation of imPact of a novel immersive technology in patient engagement of LIFe simple 7 to prevent risk of hearT disease: UPLIFT clinical Trial, Michael Castro, Aditya Vijay, Navin Govind, Moh Barathan, Leticia Medina, Aravind Upadhyaya, Krishnaswami Vijayaraghavan (2023) CMHC Supplement Abstract, *Postgraduate Medicine*, 135:sup2, 2-24, DOI: 10.1080/00325481.2023.2187148, pages 10-11. To link to this article: <https://doi.org/10.1080/00325481.2023.2187148>
100. Duell PB, Mehta V, Wong ND, Kalra D, Vijayaraghavan K, Puri R.

Management of diabetic dyslipidemia in South Asian patients: The need for individualized treatment guidelines. J Clin Lipidol. 2023 May-Jun;17(3):313-314. doi: 10.1016/j.jacl.2023.04.001. Epub 2023 Apr 17. PMID: 37117075.

- 101. Krishnaswami Vijayaraghavan(, Pankaj Jain, Renzo Cataldo, Mandeep Sahani, Navin Govind, Natalie Nabaty. Galvanize Healthy Living : Early Detection and Patient Empowerment through a Comprehensive Community Health Screening Program of Cardiometabolic Renal Disease. University of Arizona College of Medicine-Phoenix, Banner University Medical Center, Phoenix, AZ, USA, Flagstaff Medical Center, Desert Kidney Associates, Tempe, AZ, USA, and Twinepidemic Inc, Phoenix, AZ, USA. Presented at the World Congress on Non-Communicable Disease, Toronto, Canada, June 25-30, 2023.**

- 102. Navin Govind, Krishnaswami Vijayaraghavan, Harneet Bath, Moh Barathan. Utilizing Immersive technology in patient and Nursing education to improve patient outcomes in NCD. Presented at the World Congress on Non-Communicable Disease, Toronto, Canada, June 25-30, 2023.**

- 103. Karen Aspry, Krishnaswami Vijayaraghavan, Eric Brandt. Should food be medicine? Reducing cardiometabolic renal diseases and its risk factors by improving food and nutritional security Presented at the World Congress on Non-Communicable Disease, Toronto, Canada, June 25-30, 2023.**